Entinostat is a selective class I HDAC inhibitor currently in clinical development as either single agent or combination in Hodgkin's lymphoma, breast, non-small cell carcinoma, and myelodysplastic syndrome. Here, HDAC9 is linked to myelodysplastic syndrome.